Effect of Chemo- and Immunotherapy of Hemoblastosis on The Endocrine System
Keywords:
Hemoblastoses, chemotherapy, immunotherapy, checkpoint inhibitors, CAR-T therapy, hematopoietic stem cell transplantation, endocrine complications, hypothyroidism, hypophysitis, autoimmune diabetes, gonadal insufficiency.Abstract
Chemo- and immunotherapy of hemoblastoses, including leukemia, lymphoma and myeloma, are associated with the development of a wide range of acute and delayed endocrinopathies. The pathogenesis of these conditions is multifactorial and includes direct cytotoxic action, autoimmune activation, systemic inflammation and secondary effects of transplantation. The article summarizes data on the frequency, pathogenesis and clinical manifestations of endocrinopathies in oncohematological patients. Practical recommendations for their screening and monitoring, as well as on issues of fertility preservation are presented.
References
1. D'Souza A., Fretham C., Lee SJ., Arora M., Brunner J., Chhabra S., Devine S., Hamilton BK., Hayashi RJ., Hemmer M., et al. Current use of and trends in hematopoietic cell transplantation in the United States // Biol. Blood Marrow Transplant. – 2020. – Vol. 26, No. 8. – P. 177–182.
2. Barroso -Sousa R., Barry WT, Garrido -Castro AC, Hodi FS, Min L., Krop IE, Tolaney SM Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis // JAMA Oncol . – 2018. – Vol. 4, No. 2. – P. 173–182.
3. Sklar CA, Antal Z., Chemaitilly W., Cohen LE, Follin C., Meacham LR, Murad MH, Rovelli A., Schover LR, Wu FL, Yasui Y. Hypothalamic-pituitary and growth disorders in survivors of childhood cancer: an Endocrine Society Clinical Practice Guideline // J. Clin . Endocrinol . Metab . – 2018. – Vol. 103, No. 8. – P. 2761–2784.
4. Sanders JE Endocrine complications of hematopoietic cell transplantation in children and adolescents // Int. J. Pediatr . Endocrinol . – 2008. – 2008:1–10.
5. Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy – immune checkpoint blockade and associated endocrinopathies // Nat. Rev. Endocrinol . – 2017. – Vol. 13, No. 4. – P. 195–207.
6. Neelapu SS Managing the toxicities of CAR T-cell therapy // Hematol . Oncol . – 2019. – Vol. 37, Suppl. 1. – P. 48–52.
7. Tauchmanovà L., Selleri C., De Rosa G., Pagano L., Orio F., Palomba S., Lombardi G., Rotoli B., Colao A. Endocrine disorders during long-term follow-up of survivors of adult allogeneic stem cell transplantation // Bone Marrow Transplant. – 2002. – Vol. 30, No. 9. – P. 687–693.
8. Chow EJ, Liu W., Srivastava DK, Leisenring WM, Hayashi RJ, Sklar CA, Stovall M., Robison LL, Yasui Y. Differential effects of radiotherapy on growth and endocrine function among acute leukemia survivors: a Childhood Cancer Survivor Study report // Pediatr . Blood Cancer. – 2007. – Vol. 49, No. 7. – P. 102–108.
9. Stamatouli AM, Quandt Z., Perdigoto AL, Clark PL, Kluger H., Weiss SA, Gettinger S., Sznol M., Young A., Rushakoff R., Lee J., Bluestone JA, Anderson MS, Herold KC, McDonnell ME Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors // Diabetes. – 2018. – Vol. 67, No. 8. – P. 1471–1480.
10. Grupp SA, Maude SL, Shaw PA, Aplenc R., Barrett DM, Callahan C., Lacey SF, Levine BL, Melenhorst JJ, Motley L., Rheingold SR, Teachey DT, June CH, Porter DL Durable remissions in children with relapsed/refractory ALL treated with Tisagenlecleucel (CTL019) // N. Engl. J. Med. – 2016. – Vol. 374, No. 16. – P. 1507–1517.
